Amgen today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall ...

Vital3D launches a bioprinted wound patch for dogs, aiming to revolutionize pet healing now and human organ transplants ...

The smallest member of the Toyota lineup has received a mid-lifecycle update, adopting hybrid tech, a more aggressive design, ...

A techno-economic analysis has found that French cultivated meat startup Gourmey's bioreactor system can reach production ...

Anti-aging aficionados have tried it all — including taking certain drugs off-label in the hopes they will lead to longer, ...

MUMBAI, India and PRINCETON, N.J., May 30, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: ...

The presence of violations in a past inspection does not necessarily mean the establishment has the same violations today.

Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with various immunotherapies to improve outcomes in patients with non-small cell ...

They had very aggressive cancers return after several lines of therapy, including several who relapsed after an earlier stem cell transplant." Most patients (88.5% ... and low-grade graft-versus ...

Talin is a protein that plays an important role in the immune system by activating integrins, receptors that help cells ...